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A 32-kDa protein was isolated from human monocytes after calcium precipitation and chromatography. 
The protein activity was assessed by the inhibition of soluble phospholipase A 2(PLA2). This in vitro inhibi- 
tory effect on phospholipases A 2was found only with negatively charged phospholipids. The protein was 
also able to inhibit cellular PLA~ in mouse thymocytes. The biochemical properties and amino acid compo- 
sition strongly suggest that the protein shares imilarities with endonexin. Using a neutralizing monoclonal 
antibody against rat lipocortin, we found a cross-reactivity with the 32-kDa protein. According to the bio- 
chemical and immunological properties, we propose to relate this PLA 2 inhibitory protein from human 
monocytes to lipocortin. 
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1. INTRODUCTION 
Lipocortins are a family of anti- inflammatory 
proteins acting by inhibiting the activity of 
phospholipase A2, and thus preventing the forma- 
tion of inf lammatory mediators, prostaglandins 
and leukotrienes. They have been described in 
several cell systems, rat macrophages [1], rabbit 
neutrophils [2], rat renomedullary interstitial cells 
[3], human fibroblasts [4] and mouse and bovine 
thymus [5]. The predominant form is a 35-40-kDa 
protein but smaller proteolytic active fragments 
were identified. All these proteins have been 
characterized by the capacity to be induced by 
glucocorticoids, released in the supernatant of 
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treated cells and regulated by phosphorylation 
[6-9]. Recently a human lipocortin (lipocortin I) 
has been purified [10], cloned and expressed in E. 
coli [1 l]. The purified protein was identified as the 
35-kDa substrate of the EGF-receptor kinase from 
A431 cells [12], and shown to exert all the 
biochemical and pharmacological properties of 
lipocortin. The same group [13] purified from 
human placenta nother 35-kDa inhibitory protein 
which they referred to as lipocortin II. This protein 
is the human analogue of pp36, a major substrate 
for pp60 src. 
In another field of investigations, a group of 
calcium and phospholipid binding proteins has 
been identified in different cells and tissues 
(calpactin I and II, calelectrin, endonexin, protein 
I and II, calcimedin, chromobindin) [14-25]. All 
these proteins share a common characteristic con- 
sisting of a conserved 17 amino acid consensus e- 
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quence present in multiple copies [21]. They also 
have the capacity to bind phospholipids in a 
calcium dependent manner. These proteins have 
been identified in cells or tissues without glucocor- 
ticoid treatment, and were shown to be present in 
certain tissues at a high level up to 1 °7o of the total 
protein content. In this communication, we bring 
the evidence that the 32-kDa anti-phospholipase 
A2 protein from human mononuclear cells is a 
lipocortin. 
2. MATERIALS AND METHODS 
2.1. Preparation of human cells for protein 
purification 
Mononuclear cells from healthy donors (70% 
lymphocytes and 30°7o monocytes) were purified by 
sequential Ficoll-Hypaque density sedimentation, 
and continuous Percoll gradient. Cells were 
cultured at 5 x 10 6 cells/ml in RPMI 1640 medium 
(Flow Laboratories, Puteaux, France), containing 
20 mM Hepes, 2°7o Ultroser G, a serum substitute 
(IBF, Villeneuve la Garenne, France) and 1/~M 
dexamethasone and incubated in a Bellco spinner 
(Bellco, England) (25 rpm) overnight at 37°C. 
After this overnight incubation period, cells were 
reincubated in the same medium devoid of 
Ultroser for another 5 h. The cells were then 
pelleted and resuspended, after removal of red 
cells by hypotonic lysis, in buffer A (10 mM 
Hepes, 5 mM EDTA, 100 mM NaC1, 200#M 
PMSF, 1000 U/ml aprotinin, pH 7.6) and frozen 
at -80°C until use. 
2.2. Assay of phospholipase A2 inhibitory activity 
2.2.1. Using E. coli as substrate and porcine 
pancreatic phospholipase A2 
The phospholipase Az inhibitory assay was per- 
formed as described in [26] and in the accompany- 
ing paper. 
2.2.2. Using a zwitterionic or a negatively charged 
substrate and PLA2 from Naja naja 
according to Jordan, L. (personal 
communication) 
The fluorescent zwitterionic 1-palmitoyl-2-(10- 
pyrenyldecanoyl) sn-glycerol-3-phosphorylcholine 
substrate and the negatively 1-palmitoyl-2-(10-py- 
renyldecanoyl) sn-glycerol monomethyl phospha- 
tidic acid substrate (KSV Company, Helsinki, 
Finland) were used at 2/~M. The assay was 
performed at room temperature by adding sub- 
strate to a buffer solution containing 50 mM 
Tris-HCl, 100 mM NaC1 and 1 mM EDTA, pH 
7.5. Then 0.1 o7o bovine serum albumin (BSA) from 
Sigma was added and after a 2 min equilibration 
period, 0.8 ng of PLA2 was added followed by the 
fractions to be tested and the reaction initiated by 
the addition of 5 mM CaCI2 in a total volume of 
1 ml. The excitation wavelength was set at 345 nm 
and the emission wavelength at 398 nm. The slit 
width on all lamps was set at 4 nm. 
2.3. Preparation of lipocortin by Ca 2+ 
.precipitation 
Cells in buffer A were thawed and homogenized 
in a teflon-glass homogenizer and sonicated 3 x 
10 s at 4°C. The homogenate was then centrifuged 
at 20000 x g for 30 min (Sorvall RC-5B centrifuge, 
Du Pont Instruments). 6 mM of CaClz (1 mM ex- 
cess) was added to the supernatant and left for 
30 min on ice. After centrifugation at 39000 x g 
for 30 min, the pellet was washed with a buffer 
containing 10 mM Hepes, 150 mM NaC1, 1 mM 
CaC12, pH 7.4, and centrifuged at 39000 x g for 
30 min. The pellet was recovered and resuspended 
in 10 ml of a buffer containing 10 mM Hepes, 
10 mM EGTA, pH 7.60, 1000 U/ml aprotinin and 
200/~M PMSF. After centrifugation at 100000 x g 
for 30 min (TGA-65 ultracentrifuge, Kontron), the 
supernatant was used for further purification. 
2.4. Purification of phospholipase A2 inhibitory 
proteins 
The purification by fast protein liquid 
chromatography (FPLC, Pharmacia, Uppsala, 
Sweden) was carried out at room temperature. The 
volume of the calcium precipitate was adjusted to 
50 ml with buffer B containing 20 mM 
ethanolamine, 200/zM PMSF, pH 9.00, and in- 
jected onto a column of a strong anion-exchange 
resin Mono Q HR 5/5 (FPLC, Pharmacia), at a 
flow rate of 1 ml/min. After elution of unabsorb- 
ed material, a linear gradient of NaC1 was 
generated from 0 to 0.35 M over 30 min and 0.35 
to 1 M NaC1 over 15 min. Protein fractions were 
collected according to the peaks detected at 
280 nm and tested for their ability to inhibit PLA2 
activity as described. 
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2.5. SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) and isoelectric focusing (IEF) 
Gradient-SDS (10-15070 acrylamide) gels were 
run using the PHAST-SYSTEM from Pharmacia 
and proteins visualized by silver staining. IEF was 
performed under native conditions (pH gradients 
3-9) using the PHAST-SYSTEM according to the 
indications provided by the manufacturer. 
2.6. Monoclonal antibody recognition 
The chromatographic fractions were analysed by 
enzyme-linked immunosorbent assay (ELISA) us- 
ing the monoclonal antibody (BF26) raised against 
lipocortin from rat renomedullary interstitial cells 
[27]. For immunoprecipitation, the monoclonal 
antibody (at different concentrations) was in- 
cubated with the protein for 16 h at 4°C. The 
fractions were incubated with 50/zl of CNBr- 
Sepharose coupled protein A (120 mg/ml) over- 
night at 4°C. The immune complex was then 
pelleted (5 min at 10000 × g) and the resulting 
supernatant was tested for anti-PLA2 activity. In 
parallel, control experiments were done with a 
non-specific immunoglobulin (M460) of the same 
class and in the same concentrations. The antibody 
was also used in Western blot analysis by the 
method of Towbin et al. [28] using [125I]protein A 
for the immunological detection. 
2.7. Inhibition of celllular PLA2 using 
f H]arachidonic acid labeled mouse 
thymocytes 
Mouse thymocytes were labeled for 30 min at 
37°C with 5/zCi of [3H]arachidonic acid 
(128 Ci /mM, Amersham) and washed twice with 
PBS containing 0.5°7o f BSA fatty acid free (BSA- 
FAF). The labeled cells (25 000-30 000 
dpm/0.4 ml) adjusted to 4-5 × 106 cells/ml with 
MEM-Hepes, were preincubated with increasing 
concentrations of lipocortin for 20 min. The reac- 
tion was started by the addition of 50/A of the 
calcium ionophore A23187 at known concentra- 
tions and terminated 10 min later by the addition 
of 500/zl of 10 mM cold EGTA, 0.5070 BSA-FAF. 
The samples were centrifuged for 5 min and 500/zl 
of the supernatant containing released arachidonic 
acid was counted by liquid scintillation spec- 
trometry. The results are expressed in percent in- 
hibition of the stimulation obtained in the presence 
or absence of lipocortin. 
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Fig. 1. Chromatographic profile of the purified 32-kDa protein on Mono Q. The sample was applied to the column and 
the proteins eluting with a gradient of NaCI were detected by absorbance at280 nm. Fractions were collected and tested 
for their ability to inhibit phospholipase A2 activity. Hatched columns: 07o inhibition of PLA2 activity, OD, NaCl 
gradient: 0-1 M. 
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2.8. Miscellaneous 
Protein concentrat ion was measured according 
to Lowry et al. [29], and the amino acid composi -  
t ion determined according to Lederer et al. [30]. 
3. RESULTS 
3.1. Purification of  a 32-kDa protein from human 
mononuclear cells 
In the chromatographic  condit ions used, a PLA2 
inhibitory fract ion eluted as a single peak at 
0.23 M NaC1. Another  inhibitory fract ion eluted 
at 0.3 M NaCl  ( f ig. l ) .  The protein eluting at 
0.23 M NaC1 has an apparent  molecular mass of  
32 kDa and the other species of  73 kDa (fig.2a). 
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Fig.3. Dose-response curve of lipocortin on PLA2 
activity. (Left) Different concentrations of the purified 
inhibitors (32-kDa and 73-kDa) are incubated with 
0.1/~g of porcine pancreatic phospholipase A2 using E. 
coli membranes as substrate. Results are expressed in % 
inhibition of PLA2 activity. (Right) Different 
concentrations of the proteins were tested on Naja naja 
PLAz using a negatively charged (neg) and a zwitterionic 
(zwit) substrate. The rate of substrate hydrolysis 
(,aM.min l .ng- l )  is expressed vs lipocortin con- 
centration (ag). 
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Fig.2. SDS-PAGE and IEF of the eluted proteins. 
Samples from Mono Q were analyzed by SDS-PAGE 
(10-15% gradient gels) and IEF (pH gradient 3-9) and 
visualized by silver staining. (a) SDS-PAGE: Arrows on 
the left indicate the molecular mass markers, kDa: 
phosphorylase b, 94; bovine serum albumin, 67; 
ovalbumin, 43; carbonic anhydrase, 30; trypsin 
inhibitor, 20.1; o~-lactalbumin, 14.4. Lanes 1-2 
represent the analysis of two different preparations of 
the 32-kDa protein and lanes 3-4, the 73-kDa protein. 
(b) IEF: The arrows on the right represent he pI 
markers (from basic to acid): trypsinogen, 9.3; lentil 
lectin-basic band, 8.65; lentil lectin-middle band, 8.45; 
lentil lectin-acidic band, 8.15; horse myoglobin-basic 
band, 7.35; horse myoglobin-acidic band, 6.85; human 
carbonic anhydrase B, 6.55; bovine carbonic anhydrase 
B, 5.85; fl-lactoglobulin A, 5.20; soybean trypsin 
inhibitor, 4.55; amyloglucosidase, 3.50; Lane 1, pI  of 
the 32-kDa protein; lane 2, pI  values of the 73-kDa 
protein. 
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Fig.4. Inhibitory effect of the 32-kDa protein on 
[3H]arachidonic acid release from prelabeled mouse 
thymocytes. Results are expressed in % inhibition of 
arachidonic acid release vs different concentrations of
the 32-kDa protein (ug) and 3/~g of boiled lipocortin 
(3/~g b). Each point is the mean of triplicate 
determinations _+ SD. 
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Using IEF, the 32-kDa protein has a p I  of 4.80, 
whereas the 73-kDa protein shows three different 
closely migrating isoelectric forms, of 5.2, 5.3 and 
5.5 (fig.2b). 
3.2. PLA2 inhibitory properties 
1/tg of the pure 32-kDa protein gave a 50% in- 
hibition when tested with 0.1/zg of porcine 
phospholipase A2 on the E. coli substrate. The 
73-kDa protein was slightly less effective in in- 
hibiting PLA2. A typical dose response curve is 
presented in fig.3 left. After boiling, the proteins 
were shown not to be any more able to inhibit the 
enzymatic activity. 
Both proteins were inhibiting Naja naja 
phospholipase A2 when a negatively charged 
substrate was used, whereas there was no inhibi- 
tion when the substrate was zwitterionic. A typical 
dose response curve is presented in fig.3 right. 
The pure protein was also tested in another assay 
in which the cellular phospholipase A2 activity was 
monitored. The results in fig.4 show that the 
32-kDa protein was able to block [3H]arachidonic 
acid release from labeled mouse thymocytes in a 
dose dependent manner and that this activity was 
destroyed by boiling. 
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3.3. Recognition by a monoclonal antibody 
aga&st lipocortin 
Immunoreactive proteins were detected using 
the antibody in ELISA and by Western blotting 
(fig.5). The monoclonal antibody recognizes the 
32-kDa protein and another species of 36 kDa 
from the calcium precipitated fraction. Lane 2 
confirms that the pure 32-kDa inhibitory protein 
eluted from the column is effectively the one 
recognized by the antibody. In addition, the 
monoclonal antibody is able, in a dose dependent 
manner, to reverse the phospholipase A2 inhibitory 
activity of the protein using E. coli substrate 
(fig.6). A control antibody was ineffective in the 
same conditions (not shown). 
1 2 
Fig.5. Western blot analysis of the proteins using the 
monoclonal antibody (BF26) raised against rat 
lipocortin. Lane 1: protein fraction of the calcium 
precipitate. Lane 2: Mono Q fraction of the 32-kDa 
inhibitory protein eluted at 0.23 M NaC1. The arrows on 
the left represent the migration of the molecular mass 
markers; on the right, the relative molecular masses of 
the immunoreactive proteins. 
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Fig.6. Effect of increasing concentrations of the 
monoclonal antibody (BF26) on the inhibitory activity 
(e/0) of the protein using E. coli membranes a sulJstrate 
and porcine pancreatic PLA2. Each point is the mean of 
triplicate determinations +_ SD. 
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Table 1 
Amino acid composition of the 32-kDa protein 
Amino acid mol% ± SD n 
Asx 9.9 1.0 (3) 
Thr 6.0 0.3 (3) 
Ser 8.3 1.6 (3) 
Glx 13.8 0.9 (3) 
Pro 2.2 0.2 (2) 
Gly 9.3 1.2 (3) 
Ala 8.2 0.5 (3) 
Val 4.0 0.2 (3) 
Met 1.2 0.6 (2) 
lie 4.5 0.1 (3) 
Leu 10.7 0.9 (3) 
Tyr 3.8 0.6 (3) 
Phe 4.0 0.4 (3) 
His 1.5 0.4 (3) 
Lys 7.6 1.1 (3) 
Arg 5.7 0.7 (3) 
Cys N.D. 
Tryptophan and cysteine were not determined (N.D.). 
Values are expressed as mol% ± SD. n, the number of 
preparations 
3.4. Amino acid composition 
Table 1 shows the amino acid analysis of the 
32-kDa protein. 
4. DISCUSSION 
In this paper we describe the purification of two 
proteins of 32 and 73 kDa from human 
mononuclear cells based on their capacity to bind 
calcium. The identification of the proteins was 
followed by their ability to inhibit porcine pan- 
creatic and Naja naja phospholipases A2 using E. 
coli membranes and negatively charged or zwit- 
terionic substrates, respectively. In these condi- 
tions, both proteins were inhibiting the two 
enzymes in a dose dependent manner but only 
when negatively charged phospholipids were used 
as substrates. In the accompanying paper [31], we 
show that this inhibitory effect can be reversed by 
increasing the amount of substrate. These results 
as those of Davidson et al. [32] suggest hat the 
phospholipase A2 inhibition could not be due to a 
direct enzyme-inhibitor interaction. In addition we 
have found an inhibitory effect of the 32-kDa pro- 
tein on cellular phospholipase A2, indicating either 
that the enzyme was accessible from the outside of 
the cell or that the protein interacted in some way 
with the membrane phospholipids of the cell sur- 
face leading to an inhibition of the cellular en- 
zyme. Nevertheless we do not know how the 
inhibitor behaves when incubated with the whole 
cells. In the accompanying paper [31], we have 
shown that the 32 kDa protein was indeed able to 
inhibit intracellular phospholipase A2 and this 
point is discussed in the other paper. Biochemical 
studies (molecular mass, p! and amino acid com- 
position; table 1) show that the 32-kDa protein 
shares common properties with endonexin [33], 
but further experiments are necessary to prove they 
are identical. Nevertheless we could demonstrate 
that this protein was recognized by a monoclonal 
antibody raised against lipocortin indicating that 
this 32-kDa protein belongs to the lipocortin fami- 
ly. In the Western blot experiments, the antibody 
also recognized a 36-kDa protein, but did not 
reveal the 73-kDa PLAz inhibitory protein. Fur- 
ther experiments are necessary to try to correlate 
them with other lipocortin species. 
In summary, we report hat in human peripheral 
mononuclear cells, there exist proteins of the 
lipocortin family, able to bind calcium, and to in- 
hibit phospholipase A2. These cells are known to 
be targets for glucocorticosteroid action, as for the 
inhibition of prostaglandin secretion involving a 
phospholipase A2 inhibition (unpublished results). 
The 32-kDa lipocortin-like protein could be a can- 
didate for the glucocorticosteroid action in these 
cells. Presently, our data do not permit us to con- 
clude that the 32-kDa protein is the right can- 
didate, further experiments are required to test this 
hypothesis. 
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